Anti-angiogenesis therapies: their potential in cancer management

References

• CarmelietPMechanisms of angiogenesis and arteriogenesisNat Med20006438939510742145
   PubMed Web of Science ®Google Scholar
• ForsytheJAJiangBHIyerNVActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1Mol Cell Biol1996169460446138756616
   PubMed Web of Science ®Google Scholar
• YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJVascular-specific growth factors and blood vessel formationNature2000407680124224811001067
   PubMed Web of Science ®Google Scholar
• JainRKMolecular regulation of vessel maturationNat Med20039668569312778167
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience20053075706586215637262
   PubMed Web of Science ®Google Scholar
• KnockeTHWeitmannHDFeldmannHJSelzerEPotterRIntratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervixRadiother Oncol19995329910410665785
   PubMed Web of Science ®Google Scholar
• BrizelDMDodgeRKCloughRWDewhirstMWOxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcomeRadiother Oncol199953211311710665787
   PubMed Web of Science ®Google Scholar
• KakolyrisSFoxSBKoukourakisMRelationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39Br J Cancer200082484485110732757
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2007 20;25121539154417442997
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• HedrickEKozloffMHainsworthJSafety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)J Clin Oncol (Meeting Abstracts)20062418 Suppl3536
   Web of Science ®Google Scholar
• ChenHXMooneyMBoronMPhase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301J Clin Oncol200624213354336016849749
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health Fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. http://clinicaltrials.gov/ct2/show/NCT0096278 Accessed Aug 17, 2009.
   Google Scholar
• WolmarkNYothersGO’ConnellMA phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08J Clin Oncol20092718s(Suppl; abstr LBA14).
   Web of Science ®Google Scholar
• US National Institutes of Health Combination chemotherapy with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. http://clinicaltrials.gov/ct2/show/NCT00112918 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health Oxaliplatin, leucovorin, and fluorouracil with and without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. http://clinicaltrials.gov/ct2/show/NCT00217737 Accessed Aug 17, 2009.
   Google Scholar
• Oncology Clinical Trials Office (University of Oxford) A multicentre international study of capecitabine +/− bevacizumab as adjuvant treatment of colorectal cancer. http://www.octo-oxford.org.uk/alltrials/trials/q2.html Accessed Aug 17, 2009.
   Google Scholar
• National Cancer Institute FDA Approval for Bevacizumab. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab Accessed Aug 17, 2009.
   Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDChanARomieuGRandomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADOJ Clin Oncol2008261008s
   Google Scholar
• RobertNJDierasVGlaspyJRIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)J Clin Oncol20092742s(abstr 1005).
   Google Scholar
• MillerKDChapLIHolmesFARandomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancerJ Clin Oncol200523479279915681523
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration Oncology Drugs Advisory Committee Meeting 5 December 2007, AVASTIN (Bevacizumab). 2008; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4332b1-03-Genentech.pdf Accessed Nov 29, 2009.
   Google Scholar
• US National Institutes of Health Bevacizumab and combination chemotherapy in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. http://clinicaltrials.gov/ct2/show/NCT00119262 Accessed Aug 17, 2009.
   Google Scholar
• MillerKDO’NeillAPerezEASeidmanADSledgeGWPhase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104)J Clin Oncol (Meeting Abstracts). 20085202615 Suppl520
   Web of Science ®Google Scholar
• US National Institutes of Health BEATRICE study: A study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. http://clinicaltrials.gov/ct2/show/NCT00528567 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health BETH Study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. http://clinicaltrials.gov/ct2/show/NCT00625898 Accessed Aug 17, 2009.
   Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ManegoldCvon PawelJZatloukalPB017704 (AVAIL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients with advanced or recurrent non-squamous, non-small cell lung cancerAnn Oncol200819Suppl 8viii
   Google Scholar
• CloughesyTFPradosMDWenPYA phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)J Clin Oncol200826520Suppl; abstr 2010b.
   Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJECALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinomaPaper presented at: ASCO Genitourinary Cancers Symposium2008San Francisco, CA, USA
   Google Scholar
• WillettCGDudaDGdi TomasoEEfficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyJ Clin Oncol200927183020302619470921
   PubMed Web of Science ®Google Scholar
• LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00884741 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health A study of Avastin (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826 Accessed Aug 17, 2009.
   Google Scholar
• Roche Products Limited Summary of product characteristics: Avastin 25 mg/ml concentrate for solution for infusion. http://emc.medicines.org.uk/document.aspx?documentId=15748 Accessed Aug 17, 2009.
   Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• RatainMJEisenTStadlerWMPhase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol200624162505251216636341
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• BukowskiRMEisenTSzczylikCFinal results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysisJ Clin Oncol (Meeting Abstracts). 20076202518S5023
   Google Scholar
• National Cancer Institute FDA Approval for Sorafenib Tosylate. http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate Accessed Sept 16, 2009.
   Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• Bayer plc. Summary of product characteristics: Nexavar 200 mg f ilm-coated tablets. http://emc.medicines.org.uk/document.aspx?documentId=18520 Accessed Sept 30, 2009.
   Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIBukowskiRMSunitinib in patients with metastatic renal cell carcinomaJAMA2006295212516252416757724
   PubMed Web of Science ®Google Scholar
• MotzerRJMichaelsonMDRedmanBGActivity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaJ Clin Oncol2006241162416330672
   PubMed Web of Science ®Google Scholar
• SteinMNFlahertyKTCCR drug updates: sorafenib and sunitinib in renal cell carcinomaClin Cancer Res200713133765377017606705
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• National Cancer Institute FDA Approval for Sunitinib Malate. http://www.cancer.gov/cancertopics/druginfo/fda-sunitinib-malate
   Google Scholar
• US National Institutes of Health A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://clinicaltrials.gov/ct2/show/NCT00375674 Accessed Sept 30, 2009.
   Google Scholar
• US National Institutes of Health Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00326898 Accessed Sept 30, 2009.
   Google Scholar
• CasaliPGJostLReichardtPSchlemmerMBlayJYGastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-upAnn Oncol200819Suppl 2ii35ii3818456761
   PubMed Web of Science ®Google Scholar
• RubinBPGastrointestinal stromal tumours: an updateHistopathology2006481839616359540
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLDuensingAPDGFRA activating mutations in gastrointestinal stromal tumorsScience2003299560770871012522257
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMVerweijJCasaliPGInitial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyJ Clin Oncol200523245795580416110036
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• DemetriGDHuangXGarrettCRNovel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib (IM) failureJ Clin Oncol (Meeting Abstracts). 200826520Suppl: abstr 10524.
   Google Scholar
• IvySPWickJYKaufmanBMAn overview of small-molecule inhibitors of VEGFR signalingNat Rev Clin Oncol200961056957919736552
   PubMed Web of Science ®Google Scholar
• AignerAButscheidMKunkelPAn FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 releaseInt J Cancer200192451051711304685
   PubMed Web of Science ®Google Scholar
• PrestaMDell’EraPMitolaSMoroniERoncaRRusnatiMFibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine Growth Factor Rev200516215917815863032
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughnanMSFlynnEFolkmanJThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci U S A1994919408240857513432
   PubMed Web of Science ®Google Scholar
• GeitzHHandtSZwingenbergerKThalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology1996312–32132218861747
   PubMed Web of Science ®Google Scholar
• TurkBEJiangHLiuJOBinding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha productionProc Natl Acad Sci U S A19969315755275568755512
   PubMed Web of Science ®Google Scholar
• ChildJAMorganGJDaviesFEHigh-dose chemotherapy with hematopoietic stem-cell rescue for multiple myelomaN Engl J Med2003348191875188312736280
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLStoppaAMA prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myelomaN Engl J Med1996335291978649495
   PubMed Web of Science ®Google Scholar
• RajkumarSVBloodEVesoleDFonsecaRGreippPRPhase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200624343143616365178
   PubMed Web of Science ®Google Scholar
• RajkumarSVRosinolLHusseinMMulticenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myelomaJ Clin Oncol200826132171217718362366
   PubMed Web of Science ®Google Scholar
• CavoMZamagniETosiPSuperiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood20051061353915761019
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSCaravitaTOral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialLancet2006367951382583116530576
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialLancet200737095941209121817920916
   PubMed Web of Science ®Google Scholar
• HulinCFaconTRodonPEfficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trialJ Clin Oncol200927223664367019451428
   PubMed Web of Science ®Google Scholar
• Celgene Ltd Summary of product characteristics: Thalidomide Pharmion 50 mg Hard Capsules. http://emc.medicines.org.uk/document.aspx?documentId=21005 Accessed Aug 17, 2009.
   Google Scholar
• Celgene Ltd THALOMID (thalidomide): S.T.E.P.S. Program. http://www.thalomid.com/steps_program.aspx
   Google Scholar
• PalumboARajkumarSVDimopoulosMAPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia200822241442318094721
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSGertzMACombination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaJ Clin Oncol200220214319432312409330
   PubMed Web of Science ®Google Scholar
• ZangariMAnaissieEBarlogieBIncreased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyBlood20019851614161511520815
   PubMed Web of Science ®Google Scholar
• HorneMK3rdFiggWDArlenPIncreased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerPharmacotherapy200323331531812627929
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health Topotecan with or without aflibercept in treating patients with extensive-stage small cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT00828139 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). http://clinicaltrials.gov/ct2/show/NCT00561470 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health A study of alibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). http://clinicaltrials.gov/ct2/show/NCT00532155 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). http://clinicaltrials.gov/ct2/show/NCT00519285 Accessed Aug 17, 2009.
   Google Scholar
• ChuQSAflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factorsExpert Opin Biol Ther20099226327119236257
   PubMed Web of Science ®Google Scholar
• TozerGMPriseVEWilsonJMechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeabilityCancer Res200161176413642211522635
   PubMed Web of Science ®Google Scholar
• ThorpePEChaplinDJBlakeyDCThe first international conference on vascular targeting: meeting overviewCancer Res20036351144114712615734
   PubMedGoogle Scholar
• GayaAMRustinGJVascular disrupting agents: a new class of drug in cancer therapyClin Oncol (R Coll Radiol)200517427729015997924
   PubMed Web of Science ®Google Scholar
• LippertJW3rdVascular disrupting agentsBioorg Med Chem200715260561517070061
   PubMed Web of Science ®Google Scholar
• TozerGMPriseVEWilsonJCombretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissuesCancer Res19995971626163410197639
   PubMed Web of Science ®Google Scholar
• SiemannDWChaplinDJWalickePAA review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Expert Opin Investig Drugs2009182189197
   PubMed Web of Science ®Google Scholar
• RustinGNathanPBoxhallJA Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. [abstract]J Clin Oncol2005233013
   Google Scholar
• NgQGohVCarnellDPhase Ib trial of Combretastatin A4 Phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results. [abstract 3117]American Society of Clinical Oncology Annual MeetingOrlando, FL, USA2005
   Google Scholar
• AkerleyWSchabelMMorrellGA randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies [abstract 14060]American Society of Clinical Oncology Annual MeetingChicago, IL, USA2007
   Google Scholar
• RustinGJaysonGReedNFosbretabulin (combretastatin A-4 phosphate [CA4P]) carboplatin and paclitaxel is active in patients with platinum resistant ovarian cancer [abstract 315]International Gynecologic Cancer Society Meeting2008
   Google Scholar
• SiemannDWShiWDual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)Anticancer Res2008284B2027203118751370
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health Safety study of increasing doses of combretastatin in combination with bevacizumab (Avastin) in patients with advanced solid tumors. http://clinicaltrials.gov/ct2/show/NCT00395434 Accessed Aug 17, 2009.
   Google Scholar
• US National Institutes of Health A study to assess the effectiveness of the combination of carboplatin, paclitaxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naïve lung cancer. http://clinicaltrials.gov/ct2/show/NCT00653939 Accessed Aug 17, 2009.
   Google Scholar
• LanduytWAhmedBNuytsSIn vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatmentInt J Radiat Oncol Biol Phys200149244345011173139
   PubMed Web of Science ®Google Scholar
• MurataROvergaardJHorsmanMRCombretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapyInt J Radiat Oncol Biol Phys20015141018102411704326
   PubMed Web of Science ®Google Scholar
• MurataRSiemannDWOvergaardJHorsmanMRInteraction between combretastatin A-4 disodium phosphate and radiation in murine tumorsRadiother Oncol200160215516111439210
   PubMed Web of Science ®Google Scholar
• LiLRojianiASiemannDWTargeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapyInt J Radiat Oncol Biol Phys19984248999039845118
   PubMed Web of Science ®Google Scholar
• ChaplinDJPettitGRHillSAAnti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphateAnticancer Res1999191A18919510226542
   PubMed Web of Science ®Google Scholar
• NgQSGohVCarnellDTumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancerInt J Radiat Oncol Biol Phys20076751375138017275203
   PubMed Web of Science ®Google Scholar
• StevensonJPRosenMSunWPhase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flowJ Clin Oncol200321234428443814645433
   PubMed Web of Science ®Google Scholar
• DowlatiARobertsonKCooneyMA phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancerCancer Res200262123408341612067983
   PubMed Web of Science ®Google Scholar
• RustinGJGalbraithSMAndersonHPhase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic resultsJ Clin Oncol200321152815282212807934
   PubMed Web of Science ®Google Scholar